Accretion Pharmaceuticals IPO opened for subscription on May 14 and closes on May 16. The price band is set at ₹96 to ₹101 ...

Accretion Pharmaceuticals shares listed at ₹79 per share, reflecting a discount of ₹22 or 21.78 per cent over the issue price ...

Accretion Pharmaceuticals has set the price band for its IPO in the range of ₹96 to ₹101 apiece. The minimum lot size for an ...

Welnax BioClear stands out as a forward-thinking option in the evolving world of non-pharmaceutical toenail health support.

Delgocitinib cream is more effective and has a better safety profile than oral alitretinoin for the treatment of severe chronic hand eczema.

The Polysorbate 40 market is experiencing steady growth driven by rising demand across various industries, including ...

Check your kitchen and medicine cabinet for the products impacted by four major recalls this week (May 12–18). The items were ...

Accretion Pharmaceuticals Limited's Initial Public Offering opens for subscription today, May 14, 2025, marking a significant ...

Discover how the WelnaxTM BioClear LED Anti-Fungal Device is redefining at-home toenail fungus treatment in 2025 using ...

Having posted record annual revenue of $NZ208 million, AFT Pharmaceuticals says it can achieve further 50% growth over the ...

A global trade war is offering Puerto Rico hope as the U.S. territory attempts to strengthen its fragile economy.

Detailed price information for Navco Pharmaceuticals Inc (NAV-X) from The Globe and Mail including charting and trades.